Michael B Fisher

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
    Timothy J Strelevitz
    Pfizer Inc, PGRD, Pharmacokinetics, Dynamics, and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    J Pharm Sci 95:1334-41. 2006
  2. ncbi Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
    Paul S Changelian
    Immunology Group, Department of Antibacterials and Immunology, Pfizer Global Researchand Development, Groton, CT 06340, USA
    Science 302:875-8. 2003
  3. ncbi Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment
    Juntyma J Engtrakul
    Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA
    Drug Metab Dispos 33:1621-7. 2005
  4. ncbi A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma
    Sara M Skaggs
    Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism Pfizer, Inc Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 53:284-90. 2006
  5. ncbi The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism
    Michael B Fisher
    Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Curr Opin Drug Discov Devel 9:101-9. 2006
  6. doi Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems
    Daniel R Albaugh
    Boehringer Ingelheim Pharmaceuticals Inc, Medicinal Chemistry Drug Metabolism and Pharmacokinetics, 175 Briar Ridge Road, R and D 10574, Ridgefield, CT 06877, USA
    Drug Metab Dispos 40:1336-44. 2012
  7. doi Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes
    J Matthew Hutzler
    Boehringer Ingelheim Pharmaceuticals Inc, Translational Research Drug Metabolism and Pharmacokinetics, 175 Briar Ridge Road, R and D 10578, Ridgefield, CT 06877, USA
    Drug Metab Dispos 40:267-75. 2012
  8. ncbi The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective
    Michael B Fisher
    Cara Therapeutics, Tarrytown, NY 10591, USA
    Curr Drug Metab 8:694-9. 2007
  9. ncbi Recent advances in high throughput screening for ADME properties
    Timothy J Carlson
    Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    Comb Chem High Throughput Screen 11:258-64. 2008

Collaborators

  • D C Borie
  • J Matthew Hutzler
  • Daniel R Albaugh
  • Michael J Munchhof
  • Timothy J Strelevitz
  • Robert S Foti
  • Timothy J Carlson
  • Sara M Skaggs
  • Juntyma J Engtrakul
  • Paul S Changelian
  • Bret D Perry
  • Eileen A Elliott
  • Randall E Morris
  • William H Martin
  • Maryrose J Conklyn
  • Mary J Saltarelli
  • Elizabeth M Kudlacz
  • Bari Holm
  • Craig R Kent
  • Chan R Beals
  • Anderson S Gaweco
  • Brett M Lillie
  • Deborah Finco-Kent
  • James D Moyer
  • Bruce Reitz
  • Todd A Blumenkopf
  • James F Smith
  • William H Brissette
  • David A Whipple
  • Michael Larson
  • Gretchen E Beckius
  • Lisa S Hayes
  • Erika R Koslov
  • Mark E Flanagan
  • Kelly S Magnuson
  • Anthony J Milici
  • Kimberly S Johnson
  • John L Doty
  • Sandra P McCurdy
  • Ming Sing Si
  • Linda F Nelms
  • Jianmin Sun
  • Bruce H Littman
  • John Higgins
  • Jeffrey M Casavant
  • Ricardo Paniagua
  • Deanna L Baker
  • Perry S Sawyer
  • Chunyan Su
  • Chang Shang-Poa
  • Panayiotis Zagouras
  • Douglas J Ball
  • Michael Hines
  • Thasia G Woodworth
  • Holly A Magna
  • JOHN J O'SHEA
  • Chakrapani Subramanyam
  • Douglas A Fisher
  • Kwansik Yoon
  • Thomas T Kawabata
  • Yong jie Zhou
  • Bonnie J Rizzuti
  • Matthew F Brown
  • Shelley G Des Etages

Detail Information

Publications9

  1. ncbi In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
    Timothy J Strelevitz
    Pfizer Inc, PGRD, Pharmacokinetics, Dynamics, and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    J Pharm Sci 95:1334-41. 2006
    ..This method should have utility in drug discovery for the identification of factors limiting oral bioavailability...
  2. ncbi Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
    Paul S Changelian
    Immunology Group, Department of Antibacterials and Immunology, Pfizer Global Researchand Development, Groton, CT 06340, USA
    Science 302:875-8. 2003
    ..On the basis of these preclinical results, we believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clinical settings...
  3. ncbi Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment
    Juntyma J Engtrakul
    Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA
    Drug Metab Dispos 33:1621-7. 2005
    ....
  4. ncbi A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma
    Sara M Skaggs
    Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism Pfizer, Inc Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 53:284-90. 2006
    ..This can be time consuming for multiple compounds since it requires separate experiments to determine in vitro lability, and free fraction...
  5. ncbi The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism
    Michael B Fisher
    Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Curr Opin Drug Discov Devel 9:101-9. 2006
    ..The concepts and evidence behind this phenomenon as it relates to complexities in blocking metabolic clearance are presented herein...
  6. doi Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems
    Daniel R Albaugh
    Boehringer Ingelheim Pharmaceuticals Inc, Medicinal Chemistry Drug Metabolism and Pharmacokinetics, 175 Briar Ridge Road, R and D 10574, Ridgefield, CT 06877, USA
    Drug Metab Dispos 40:1336-44. 2012
    ..Overall, results from these studies suggest that in vitro inactivation parameters generated from plated cell systems may be a practical approach for identifying time-dependent inhibitors and for estimating the magnitude of clinical DDIs...
  7. doi Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes
    J Matthew Hutzler
    Boehringer Ingelheim Pharmaceuticals Inc, Translational Research Drug Metabolism and Pharmacokinetics, 175 Briar Ridge Road, R and D 10578, Ridgefield, CT 06877, USA
    Drug Metab Dispos 40:267-75. 2012
    ..These data taken together suggest that the use of cryopreserved hepatocytes may be a practical approach for assessing AO-mediated metabolism in discovery and potentially useful for predicting hepatic clearance of AO substrates...
  8. ncbi The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective
    Michael B Fisher
    Cara Therapeutics, Tarrytown, NY 10591, USA
    Curr Drug Metab 8:694-9. 2007
    ..The opportunity exists to increase the examination of intestinal metabolism of drugs and drug candidates in industry...
  9. ncbi Recent advances in high throughput screening for ADME properties
    Timothy J Carlson
    Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    Comb Chem High Throughput Screen 11:258-64. 2008
    ..Future advances will further improve the ability to make decisions on molecules earlier in drug discovery...